can özlü

doktor
@dengeband

[ABD Borsa Rehberi @bugra_kurtoglu]

💸 500.000 TL'lik yatırım ne kadar yıllık temettü üretir?

500 bin TL $DGRO, yıllık 10.050 TL temettü.
500 bin TL $HDV, yıllık 14.350 TL temettü.
500 bin TL $SCHD, yıllık 16.750 TL temettü.
500 bin TL $JEPI, yıllık 40.600 TL temettü.
500 bin TL $GPIX, yıllık 41.350 TL temettü.
500 bin TL $JEPQ, yıllık 53.500 TL temettü.
500 bin TL $QQQI, yıllık 70.950 TL temettü.

[Spartaküs #Fenerbahçe @Hasan20597455]

REZALETE DUR DEYİN @UEFA

Erman Toroğlu: "Bana soracaklarınızı Galatasaray Başkanı ve TFF Başkanına sorun" diye açıklama yapmış.

Adam kendinden emin belliki Tff içinden birinden duymuş. Burdan @UEFA yetkililerine sesleniyorum m takımı soruşturun !

[Gökhan Özoğuz @gokhanozoguz]

Adalet istiyoruz.
@GalatasaraySK gölgeli şampiyonlukları incelenip geri alınmalıdır.
Ve yapmış oldukları yasa dışı hamleler yüzünden cezalandırılıp küme düşürülmelidir!

@Fenerbahce nin 3 temmuz olaylarında gerçekliği olmadığı halde yaşadıklarının aynısını bu sefer gerçek oldukları için yapılmasını talep ediyoruz.

#Adaletİstiyoruz
#rizevsGs

[Gökhan Özoğuz @gokhanozoguz]

Attention please

@UEFA
As football supporters, we would like to express our serious concerns regarding the Galatasaray vs. Rizespor match, as well as numerous previous matches, where refereeing and VAR-related decisions have repeatedly raised questions about fairness.

These issues are widely recognized by the football community, and we respectfully request that a formal investigation be initiated, along with the necessary actions to ensure transparency and sporting integrity.
⚽️ #FairPlay #FootballJustice

We formally request that the matches of this team be thoroughly reviewed.

Over the past ten years, they have won five league titles and qualified for the UEFA Champions League on multiple occasions, amid recurring concerns related to questionable refereeing and VAR decisions. These ongoing issues raise serious doubts about sporting fairness and integrity.

We respectfully ask that this request for investigation be taken seriously and that the necessary examinations be conducted to protect the principles of justice and transparency in football.

[Medicine Pods @MedicinePods]

🩸 Hemolysis made simple.

Intrinsic vs extrinsic, DAT+ vs DAT−, immune vs non-immune — all on one high-yield page you’ll actually remember.

📌 Save this for wards & exams: https://t.co/QHKsnW7zkt

#MedPods #HemeTwitter

[Benlazar S M A @smbenlazar]

Chemotherapy‐Sparing Strategies in Follicular Lymphoma: Emerging Targeted and Immune‐Based Approaches - Martino - European Journal of Haematology - Wiley Online Library https://t.co/RRKojMfSBz #lymsm

[Ahmed Kotb @AhmedKo45911157]

🩸R/R LBCL: BSH guide

⏱️Relapse ≤12 months:
✔️ Fit → CAR-T preferred
❌ Unfit → R-GemOx / Glofit-GemOx, Pola-BR, Tafa-len

⏱️ Relapse >12 months:
🔁 Re-induction → response? → Auto-SCT
➡️ CAR-T or bispecifics in later lines

🎯 Treatment guided by timing, fitness, response

[sarp akkaya @akkayasarp]

Yargılanacaksınız!!! @GalatasaraySK

[can özlü @drcanozlu]

Peripheric T cell lymphoma treatment algorithm

[Çubuklu Sports @SportsCubuklu]

Nasıl da utanmadan anlatabiliyor bunları ya?

Bu camianın her oyuncusu mu ahlaksız, kötü olabilir!

https://t.co/DT784PXaET

[Ahmed Kotb @AhmedKo45911157]

Marginal zone #lymphoma
📌Stage IV EMZL/MZL –ESMO2025

🔹Gastric EMZL
•If H. pylori + →Eradication therapy→
 ▫Asymptomatic→ Watch &wait
 ▫Symptomatic → Systemic therapy(R-based)

🔹Non-gastric MZL
•Start systemic therapy (R-chlorambucil, BR, R-CHOP, etc)based on symptoms

[Benlazar S M A @smbenlazar]

Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management https://t.co/CZjw2wDeRy #AML #leusm

[Benlazar S M A @smbenlazar]

Proposed therapeutic algorithm for mantle cell lymphoma including both clinically available and experimental drugs, expected in the near future https://t.co/P3zroMzF2C #lymsm

[Nico Gagelmann @NicoGagelmann]

What a #EHA2025, with multiple high-quality simultaneous publications!

Congrats @EHA_Hematology and all presenters!

Here are the most impressive malignant hematology studies🧵

[Dr. Medica🩺 @DrMedica_13]

Leukaemia 🩸

✨✨✨

[AmericanJournalofHematology @AjHematology]

CPX-351 (Vyxeos) in acute myeloid leukemia: Time to move on? #AML #LeuSM
https://t.co/z6n5zTKxnF

[Vincent Rajkumar @VincentRK]

Key Myeloma therapy update for 2025

1) Newly diagnosed: Start treatment with quads, if possible. (Dara-VRd or Isa-VRd).

2) Auto Transplant: can be deferred for standard risk patients, especially if good response to induction. But collect and store stem cells for future use.

3) Maintenance: Doublet maintenance with Dara/ Len or bortezomib/ Len for high risk myeloma. Either Single or Doublet maintenance for standard risk.

4) Use new IMWG IMS risk stratification

5) First relapse: standard triplet therapy is fine for most. CART in first relapse mainly for functional high risk (progression or early relapse with induction).

6) When using CART, disease burden should be controlled and minimal to reduce risk of serious toxicity.

[Medical Info @Medicalinfo111]

Approach to ITP

[Rheuma Doc @LastManStand85]

Treatment algorithm for #VEXAS
#Rheumatology #EULAR2025 👇

[Dr Ai Lyn Tan @DrAiLynTan]

Neutrophils pivotal in #Behcet's syndrome pathogenesis↔️Target for therapy

▶️Infliximab superior to cyclophosphamide for induction
▶️Adalimumab superior to cyclosporin to reduce uveitis relapse

via @RMD_clinic #EULAR2025